Astellas wins Flomax patent suit against Ranbaxy
TOKYO, Feb 23 (Reuters) - Japan's Astellas Pharma Inc. (4503.T) said on Friday it had won a suit against Ranbaxy Laboratories Ltd. (RANB.BO) to prevent the Indian drug maker from releasing an early generic version of its Flomax prostate drug. Astellas, Japan's third-largest drug maker and Germany's Boehringer Ingelheim, which jointly market the drug in the United States, had filed the suit at the U.S. District Court of New Jersey.
The U.S. patent on Flomax, used to treat enlarged prostates, expires in Oct. 2009.
((Reporting by Edwina Gibbs, editing by Sophie Hardach; Reuters messaging: edwina.gibbs.reuters.com@reuters.net; email edwina.gibbs.@reuters.com; +81 3 3432-8720)) Keywords: ASTELLAS RANBAXY/FLOMAX
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nT207619








